In the books.. Perhaps 1st Lead Free #EVAR w/ @RAMPARTic’s, #Guardian for #Radiation ☢️ protection in 🌎? 2 RTs, 1 RN, 2 MDs 1 #Guardian & 0 vests, 0 aprons, 0 glasses… Barrier Protection = 0.3 mRem! Total Body & Team Protection @VascularSVS @VEITHsymposium @ESVSmembership

Great attendance #vam2025 strong work @ahmed175117 presenting optimal timing >3mos to stage bilateral carotid revasc procedures @UCSDHealth @UCSDsurgery

Welcome to #VAM2025 #VAM25! Here is the first of our Simultaneous Presentation and Publication #Simulpub articles! 1 Year Outcome of TAMBE. https://t.co/ma3zFgarMP

Next up: Dr. @malas_mahmoud presents "Bypass Versus Endovascular Therapy for Elective Infrapopliteal Interventions in Chronic Limb-Threatening Ischemia: Propensity Score-Matched Analyses of Vascular Quality Initiative Registry"🦵#AmerSurg25

Excited to take on this new role. @hopkinssurgery has so many amazing faculty doing very exciting work, and I hope we can continue to grow that. Thanks @AndrewMCameron @JamesHBlackMD for the opportunity!

Confirming my bias. I send patients home if they did not take the P2Y12 inhibitor we prescribed to take at least five days prior to TCAR or TFCAS. Don’t load

Ann Gaffey, M.D., M.S., is passionate about her research and meaningful patient relationships. Outside of surgery, she enjoys sailing and mountain biking. #UCSDSurgery #HumansofSurgery #Vascular #Endovascular 🔗: https://t.co/VhL5D0kBgB

Excellent attendance @SouthernVasc despite the gorgeous beaches and amazing weather at St. Thomas USVI. Good discussion of @UCSDsurgery superb analysis by Dr Narek Veranyan showing that additional branch intervention reduces risk of mortality in pts with TBAD with malperfusion

Excellent presentation by Mo Hamouda at @SouthernVasc presenting outcomes of CKD patients in the BEST-CLI trial, <50% 3-yrs survival in patients on dialysis. GFR<30 , based on spline model, predicts worse outcomes @BEST_CLI @UCSDsurgery @VascularSVS

Thanks Mike for posting our work. Always try to confirm my bias and anecdotal experience with the best possibly designed study. Clearly not level 1 evidence but confirm what many of us have experience. No staples allowed on my patients following LE bypass

Congratulations @GWSurgChair Could not think of more well- deserving leader with endless life long accomplishments and impactful contributions in the field of both general and vascular surgery

Dr. Anton Sidawy Is ACS President-Elect

Excited to announce our vascular faculty recruitment @UCSDsurgery Humbled by our team’s accomplishments: matured 0/5 residency, >10,000 accredited vasc lab studies/yr, AAHC accredited OBL, CLEVER with 40 pubs/yr, IDE, and home of vascular RO1!

Very comprehensive presidential address @jmills1955 emphasizing numerous remarkable achievements by @VascularSVS #VAM24 proud to be a vascular surgeon and a member of our society

Kicking off day 2 of #VAM24 @KateMcGinigleMD shares stratified analysis in @BEST_CLI. Females had lower MALE with any open conduit SSGSV + alternative conduits compared to endo, and lower rates of major amputation compared to males.

Superb presentation @Nishi_Vootukuru @VascularSVS #VAM24 significant number of bedridden/wheelchair asymptomatic patients undergoing CEA with 2.6folds increase 30day death risk compared to ambulatory patients. These patients are better off with BMT @UCSDsurgery

Proud to be part of the new Center for Healthcare Cybersecurity @UCSDHealthSci! Thank you Drs. Tully and Dameff for your leadership in this important space 🖥️ 🏥

Super proud of Dr. Elsie Ross @tyingwithpolish Associate Professor of Vascular Surgery In-Residence @UCSDsurgery for securing funding of her R-01 using #Al for early Detection of Peripheral Artery Disease (AID-PAD)

Q4: With evolving BMT, will asymptomatic revascularization become obsolete? How do we optimize training of comprehensive carotid management while maintaining appropriateness of care? #jvscitXchat @VascularMaximus @KatDiLosa @rmotagsanahalli @CaitlinWHicks @malas_mahmoud

https://t.co/2ZmIXloqWb